Artesunate-erythropoietin combination for murine cerebral malaria treatment

Acta Tropica

Volumn 106, Issue 2, 2008, Pages 104-108

  Bienvenu, Anne Lise ^a   Ferrandiz, Josette ^a   Kaiser, Karine ^a   Latour, Christine ^a   Picot, Stéphane ^a  

^a UNIVERSITÉ LYON 1   (France)

Author keywords

Adjunctive therapy; Artesunate; Cerebral malaria; Erythropoietin; Plasmodium berghei ANKA

Indexed keywords

ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; ARTESUNATE; QUININE; RECOMBINANT ERYTHROPOIETIN;

ANTIMALARIAL AGENT; COMPARATIVE STUDY; DISEASE TREATMENT; DRUG DEVELOPMENT; MALARIA; MORTALITY; PROTOZOAN; RODENT; SURVIVAL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN MALARIA; CEREBROVASCULAR ACCIDENT; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CONVALESCENCE; DISEASE SEVERITY; DRUG EFFICACY; FATALITY; FEMALE; IMMUNOMODULATION; MALARIA; MONOTHERAPY; MORTALITY; MOUSE; NONHUMAN; PLASMODIUM FALCIPARUM; SURVIVAL RATE; TREATMENT OUTCOME;

ANIMALS; ARTEMISININS; DRUG THERAPY, COMBINATION; ERYTHROPOIETIN; FEMALE; MALARIA, CEREBRAL; MICE; MICE, INBRED CBA; PLASMODIUM BERGHEI; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

ARTESUNATE; MURINAE; MUS; PLASMODIUM BERGHEI; PLASMODIUM FALCIPARUM;

EID: 42649093779     PISSN: 0001706X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.actatropica.2008.02.001     Document Type: Article

References (48)

1. Ashley E.A., and White N.J. Artemisinin-based combinations. Curr. Opin. Infect. Dis. 18 (2005) 531-536
2. Bacon D.J., Latour C., Lucas C., Colina O., Ringwald P., and Picot S. Comparison of a SYBR Green I-based assay with a histidine-rich protein II enzyme-linked immunosorbent assay for in vitro antimalarial drug efficacy testing and application to clinical isolates. Antimicrob. Agents Chemother. 51 (2007) 1172-1178
3. Birbeck G.L. Cerebral malaria. Curr. Treat. Options Neurol. 6 (2004) 125-137
4. Brines M., and Cerami A. Emerging biological roles for erythropoietin in the nervous system. Nat. Rev. Neurosci. 6 (2005) 484-494
5. Brines M., and Cerami A. Discovering erythropoietin's extra-hematopoietic functions, biology and clinical promise. Kidney Int. 70 (2006) 246-250
6. Chong Z.Z., and Maiese K. Erythropoietin involves the phosphatidylinositol 3-kinase pathway, 14-3-3 protein and FOXO3a nuclear trafficking to preserve endothelial cell integrity. Br. J. Pharmacol. 150 (2007) 839-850
7. Coltel N., Combes V., Hunt N.H., and Grau G.E. Cerebral malaria - a neurovascular pathology with many riddles still to be solved. Curr. Neurovasc. Res. 1 (2004) 91-110
8. Di Perri G., Di Perri I.G., Monteiro G.B., Bonora S., Hennig C., Cassatella M., Micciolo R., Vento S., Dusi S., and Bassetti D. Pentoxifylline as a supportive agent in the treatment of cerebral malaria in children. J. Infect. Dis. 171 (1995) 1317-1322
9. Djadou K.E., Komlangan A., Balaka B., Dokounor D., Gbadoe A.D., Atakouma D., Agbere A.D., Kessie K., and Assimadi K. Management of children severe malaria in Tsevie's (Togo) hospital regional center. Arch. Pediatr. 13 (2006) 1555-1556
10. Dondorp A., Nosten F., Stepniewska K., Day N., and White N. South East Asian Quinine Artesunate Malaria Trial (SEAQUAMAT) group. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet 366 (2005) 717-725
11. Ehrenreich H., Hasselblatt M., Dembowski C., Cepek L., Lewczuk P., Stiefel M., Rustenbeck H.H., Breiter N., Jacob S., Knerlich F., Bohn M., Poser W., Rüther E., Kochen M., Gefeller O., Gleiter C., Wessel T.C., De Ryck M., Itri L., Prange H., Cerami A., Brines M., and Siren A.L. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol. Med. 8 (2002) 495-505
12. Ehrenreich H., Aust C., Krampe H., Jahn H., Jacob S., Herrmann M., and Siren A.L. Erythropoietin: novel approaches to neuroprotection in human brain disease. Metab. Brain Dis. 19 (2004) 195-206
13. Engwerda C., Belnoue E., Gruner A.C., and Renia L. Experimental models of cerebral malaria. Curr. Top. Microbiol. Immunol. 297 (2005) 103-143
14. Fiordaliso F., Chimenti S., Staszewsky L., Bai A., Carlo E., Cuccovillo I., Doni M., Mengozzi M., Tonelli R., Ghezzi P., Coleman T., Brines M., Cerami A., and Latini R. A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 2046-2051
15. Franco-Paredes C., Dismukes R., Nicolls D., and Kozarsky P.E. Neurotoxicity due to antimalarial therapy associated with misdiagnosis of malaria. Clin. Infect. Dis. 40 (2005) 1710-1711
16. Ghezzi P., and Brines M. Erythropoietin as an antiapoptotic, tissue-protective cytokine. Cell. Death Differ. 11 (2004) S37-S44
17. Golenser J., McQuillan J., Hee L., Mitchell A.J., and Hunt M.H. Conventional and experimental treatment of cerebral malaria. Int. J. Parasitol. 36 (2006) 583-593
18. Golenser J., Waknine J.H., Krugliak M., Hunt N.H., and Grau G.E. Current perspectives on the mechanism of action of artemisinins. Int. J. Parasitol. 36 (2006) 1427-1441
19. Grau G.E., Fajardo L.F., Piguet P.F., Allet B., Lambert P.H., and Vassalli P. Tumor necrosis factor (cachectin) as an essential mediator in murine cerebral malaria. Science 237 (1987) 1210-1212
20. Gumede B., Folb P., and Ryffel B. Oral artesunate prevents Plasmodium berghei Anka infection in mice. Parasitol. Int. 52 (2003) 53-59
21. Hasselblatt M., Ehrenreich H., and Siren A.L. The brain erythropoietin system and its potential for therapeutic exploitation in brain disease. J. Neurosurg. Anesthesiol. 18 (2006) 132-138
22. van Hensbroek M.B., Palmer A., Onyiorah E., Schneider G., Jaffar S., Dolan G., Memming H., Frenkel J., Enwere G., Bennett S., Kwiatkowski D., and Greenwood B. The effect of a monoclonal antibody to tumor necrosis factor on survival from childhood cerebral malaria. J. Infect. Dis. 174 (1996) 1091-1097
23. Idro R., Jenkins N.E., and Newton C.R. Pathogenesis, clinical features, and neurological outcome of cerebral malaria. Lancet Neurol. 4 (2005) 827-840
24. Idro R., Aketch S., Gwer S., Newton C.R.J.C., and Maitland K. Research priorities in the management of severe Plasmodium falciparum malaria in children. Ann. Trop. Med. Parasitol. 100 (2006) 95-108
25. Juul S.E., McPherson R.J., Farrell F.X., Jolliffe L., Ness D.J., and Gleason C.A. Erytropoietin concentrations in cerebrospinal fluid of nonhuman primates and fetal sheep following high-dose recombinant erythropoietin. Biol. Neonate 85 (2004) 138-144
26. Kaiser K., Texier A., Ferrandiz J., Buguet A., Meiller A., Latour C., Peyron F., Cespuglio R., and Picot S. Recombinant human erythropoietin prevents the death of mice during cerebral malaria. J. Infect. Dis. 193 (2006) 987-995
27. Kumar S., and Srivastava S. Establishment of artemisinin combination therapy as first line treatment for combating malaria. Artemisia annua cultivation in India needed for providing sustainable supply chain of artemisinin. Curr. Sci. 89 (2005) 1097-1102
28. Leist M., Ghezzi P., Grasso G., Bianchi R., Villa P., Fratelli M., Savino C., Bianchi M., Nielsen J., Gerwien J., Kallunki P., Larsen A.K., Helboe L., Christensen S., Pedersen L.O., Nielsen M., Torup L., Sager T., Sfacteria A., Erbayraktar S., Erbayraktar Z., Gokmen N., Yilmaz O., Cerami-Hand C., Xie Q.W., Coleman T., Cerami A., and Brines M. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 305 (2004) 239-242
29. Li F., Chong Z.Z., and Maiese K. Erythropoietin on a tightrope: balancing neuronal and vascular protection between intrinsic and extrinsic pathways. Neurosignals 13 (2004) 265-289
30. Li Q., Xie L.H., Si Y., Wong E., Upadhyay R., Yanez D., and Weina P.J. Toxicokinetics and hydrolysis of artelinate and artesunate in malaria-infected rats. Int. J. Toxicol. 24 (2005) 241-250
31. Lou J., Lucas R., and Grau G.E. Pathogenesis of cerebral malaria: recent experimental data and possible applications for humans. Clin. Microbiol. Rev. 14 (2001) 810-820
32. Ma X., Abboud F.M., and Chapleau M.W. Neurocardiovascular regulation in mice: experimental approaches and novel findings. Clin. Exp. Pharmacol. Physiol. 30 (2003) 885-893
33. Mackintosh C.L., Beeson J.G., and Marsh K. Clinical features and pathogenesis of severe malaria. Trends Parasitol. 20 (2004) 597-603
34. Martinez-Estrada O.M., Rodriguez-Millan E., Gonzalez-De Vicente E., Reina M., Vilaro S., and Fabre M. Erythropoietin protects the in vitro blood-brain barrier against VEGF-induced permeability. Eur. J. Neurosci. 18 (2003) 2538-2544
35. Mturi N., Musumba C.O., Wamola B.M., Ogutu B.R., and Newton C.R. Cerebral malaria: optimising management. CNS Drugs 17 (2003) 153-165
36. Newton C.R., and Krishna S. Severe falciparum malaria in children: current understanding of pathophysiology and supportive treatment. Pharmacol. Ther. 79 (1998) 1-53
37. Newton P., Suputtamongkol Y., Teja-Isavadharm P., Pukrittayakamee S., Navaratnam V., Bates I., and White N. Antimalarial bioavailability and disposition of artesunate in acute falciparum malaria. Antimicrob. Agents Chemother. 44 (2000) 972-977
38. Newton P.N., Day N.P.J., and White N.J. Misattribution of central nervous system dysfunction to artesunate. CID 41 (2005) 1687-1688
39. Safeukui-Noubissi I., Ranque S., Poudiougou B., Keita M., Traore A., Traore D., Diakite M., Cisse M.B., Keita M.M., Dessein A., and Doumbo O.K. Risk factors for severe malaria in Bamako, Mali: a matched case-control study. Microbes Infect. 6 (2004) 572-578
40. Siren A.L., Fratelli M., Brines M., Goemans C., Casagrande S., Lewczuk P., Keenan S., Gleiter C., Pasquali C., Capobianco A., Mennini T., Heumann R., Cerami A., Ehrenreich H., and Ghezzi P. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 4044-4049
41. de Souza J.B., and Riley E.M. Cerebral malaria: the contribution of studies in animal models to our understanding of immunopathogenesis. Microbes Infect. 4 (2002) 291-300
42. Teja-Isavadharm P., Peggins J.O., Brewer T.G., White N.J., Webster H.K., and Kyle D.E. Plasmodium falciparum-based bioassay for measurement of artemisinin derivatives in plasma or serum. Antimicrob. Agents Chemother. 48 (2004) 954-960
43. Thuma P.E., Mabeza G.F., Biemba G., Bhat G.J., McLaren C.E., Moyo V.M., Zulu S., Khumalo H., Mabeza P., M'Hango A., Parry D., Poltera A.A., Brittenham G.M., and Gordeuk V.R. Effect of iron chelation therapy on mortality in Zambian children with cerebral malaria. Trans. R. Soc. Trop. Med. Hyg. 92 (1998) 214-218
44. Trager W., and Jensen J.B. Human malaria parasites in continuous culture. Science 193 (1976) 673-675
45. Villa P., Bigini P., Mennini T., Agnello D., Laragione T., Cagnotto A., Viviani B., Marinovich M., Cerami A., Coleman T.R., Brines M., and Ghezzi P. Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis. J. Exp. Med. 198 (2003) 971-975
46. Villa P., van Beek J., Larsen A.K., Gerwien J., Christensen S., Cerami A., Brines M., Leist M., Ghezzi P., and Torup L. Reduced functional deficits, neuroinflammation, and secondary tissue damage after treatment of stroke by nonerythropoietic erythropoietin derivatives. J. Cereb. Blood Flow Metab. 27 (2007) 552-563
47. Wilson M.E. Parenteral artesunate for treatment of severe malaria. Curr. Infect. Dis. Rep. 8 (2006) 33-34
48. Xie L.H., Johnson T.O., Weina P.J., Si Y., Haeberle A., Upadhyay R., Wong E., and Li Q. Risk assessment and therapeutic indices of artesunate and artelinate in Plasmodium berghei-infected and uninfected rats. Int. J. Toxicol. 24 (2005) 251-264